These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 27813428)

  • 1. How may targeted proteomics complement genomic data in breast cancer?
    Guerin M; Gonçalves A; Toiron Y; Baudelet E; Audebert S; Boyer JB; Borg JP; Camoin L
    Expert Rev Proteomics; 2017 Jan; 14(1):43-54. PubMed ID: 27813428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of reverse phase protein array (RPPA)-based pathway-activation profiling in 84 non-small cell lung cancer (NSCLC) cell lines as platform for cancer proteomics and biomarker discovery.
    Ummanni R; Mannsperger HA; Sonntag J; Oswald M; Sharma AK; König R; Korf U
    Biochim Biophys Acta; 2014 May; 1844(5):950-9. PubMed ID: 24361481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteomic analysis of breast tumors confirms the mRNA intrinsic molecular subtypes using different classifiers: a large-scale analysis of fresh frozen tissue samples.
    Waldemarson S; Kurbasic E; Krogh M; Cifani P; Berggård T; Borg Å; James P
    Breast Cancer Res; 2016 Jun; 18(1):69. PubMed ID: 27357824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor antigens as proteogenomic biomarkers in invasive ductal carcinomas.
    Olsen L; Campos B; Winther O; Sgroi DC; Karger BL; Brusic V
    BMC Med Genomics; 2014; 7 Suppl 3(Suppl 3):S2. PubMed ID: 25521819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteomic classification of breast cancer.
    Kamel D; Brady B; Tabchy A; Mills GB; Hennessy B
    Curr Drug Targets; 2012 Nov; 13(12):1495-509. PubMed ID: 22974393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Which path to follow? Utilizing proteomics to improve therapy choices for breast cancer patients.
    Blucher AS; Mills GB; Tsang YH
    Expert Rev Proteomics; 2020 Mar; 17(3):187-190. PubMed ID: 32306787
    [No Abstract]   [Full Text] [Related]  

  • 7. Harnessing the power of proteomics for identification of oncogenic, druggable signalling pathways in cancer.
    Murray HC; Dun MD; Verrills NM
    Expert Opin Drug Discov; 2017 May; 12(5):431-447. PubMed ID: 28286965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implications of functional proteomics in breast cancer.
    Chae YK; Gonzalez-Angulo AM
    Oncologist; 2014 Apr; 19(4):328-35. PubMed ID: 24664486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigation of HER2 expression in canine mammary tumors by antibody-based, transcriptomic and mass spectrometry analysis: is the dog a suitable animal model for human breast cancer?
    Burrai GP; Tanca A; De Miglio MR; Abbondio M; Pisanu S; Polinas M; Pirino S; Mohammed SI; Uzzau S; Addis MF; Antuofermo E
    Tumour Biol; 2015 Nov; 36(11):9083-91. PubMed ID: 26088453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Global proteomics profiling improves drug sensitivity prediction: results from a multi-omics, pan-cancer modeling approach.
    Ali M; Khan SA; Wennerberg K; Aittokallio T
    Bioinformatics; 2018 Apr; 34(8):1353-1362. PubMed ID: 29186355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrating meta-analysis of microarray data and targeted proteomics for biomarker identification: application in breast cancer.
    Pavlou MP; Dimitromanolakis A; Martinez-Morillo E; Smid M; Foekens JA; Diamandis EP
    J Proteome Res; 2014 Jun; 13(6):2897-909. PubMed ID: 24799281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Dawning of Translational Breast Cancer: From Bench to Bedside.
    Chen X; Fan S; Song E
    Adv Exp Med Biol; 2017; 1026():1-25. PubMed ID: 29282677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glioma tumor proteomics: clinically useful protein biomarkers and future perspectives.
    Ghantasala S; Gollapalli K; Epari S; Moiyadi A; Srivastava S
    Expert Rev Proteomics; 2020 Mar; 17(3):221-232. PubMed ID: 32067544
    [No Abstract]   [Full Text] [Related]  

  • 14. Translational Genomics: Practical Applications of the Genomic Revolution in Breast Cancer.
    Yates LR; Desmedt C
    Clin Cancer Res; 2017 Jun; 23(11):2630-2639. PubMed ID: 28572257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deciphering lymphoma pathogenesis via state-of-the-art mass spectrometry-based quantitative proteomics.
    Psatha K; Kollipara L; Voutyraki C; Divanach P; Sickmann A; Rassidakis GZ; Drakos E; Aivaliotis M
    J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Mar; 1047():2-14. PubMed ID: 27979587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer proteomics: developments in technology, clinical use and commercialization.
    Yeat NC; Lin C; Sager M; Lin J
    Expert Rev Proteomics; 2015 Aug; 12(4):391-405. PubMed ID: 26145529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrated proteo-genomic approach for early diagnosis and prognosis of cancer.
    Shukla HD; Mahmood J; Vujaskovic Z
    Cancer Lett; 2015 Dec; 369(1):28-36. PubMed ID: 26276717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unravelling the biology of chromatin in health and cancer using proteomic approaches.
    Eubanks CG; Dayebgadoh G; Liu X; Washburn MP
    Expert Rev Proteomics; 2017 Oct; 14(10):905-915. PubMed ID: 28895440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative proteomic analysis in breast cancer.
    Tabchy A; Hennessy BT; Gonzalez-Angulo AM; Bernstam FM; Lu Y; Mills GB
    Drugs Today (Barc); 2011 Feb; 47(2):169-82. PubMed ID: 21431104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular insights into cancer drug resistance from a proteomics perspective.
    An Y; Zhou L; Huang Z; Nice EC; Zhang H; Huang C
    Expert Rev Proteomics; 2019 May; 16(5):413-429. PubMed ID: 30925852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.